NASDAQ:VCYTVeracyte Stock Price, Forecast & News

Veracyte's stock was trading at $23.55 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, VCYT stock has increased by 8.7% and is now trading at $25.59. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Veracyte.

Veracyte is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Veracyte.

Veracyte Inc (NASDAQ:VCYT) issued its quarterly earnings results on Wednesday, May, 6th. The biotechnology company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by $0.06. The biotechnology company had revenue of $31.12 million for the quarter, compared to analyst estimates of $30.31 million. Veracyte had a negative net margin of 18.36% and a negative return on equity of 9.68%. View Veracyte's earnings history.

Veracyte issued an update on its first quarter 2020 After-Hours earnings guidance on Thursday, April, 16th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $30.5-31.5 million, compared to the consensus revenue estimate of $30.35 million.

3 equities research analysts have issued 12 month target prices for Veracyte's shares. Their forecasts range from $30.00 to $35.00. On average, they anticipate Veracyte's stock price to reach $32.33 in the next year. This suggests a possible upside of 26.4% from the stock's current price. View analysts' price targets for Veracyte.

News coverage about VCYT stock has been trending extremely negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Veracyte earned a coverage optimism score of -4.5 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the next few days. View the latest news aboutVeracyte.

Veracyte saw a decrease in short interest during the month of April. As of April 15th, there was short interest totaling 4,980,000 shares, a decrease of 7.4% from the March 31st total of 5,380,000 shares. Based on an average daily trading volume, of 498,300 shares, the short-interest ratio is presently 10.0 days. Currently, 10.5% of the shares of the company are short sold. View Veracyte's Current Options Chain.

Some companies that are related to Veracyte include ELEKTA AB/ADR (EKTAY), Natera (NTRA), InVitae (NVTA), CareDx (CDNA), RadNet (RDNT), Castle Biosciences (CSTL), Personalis (PSNL), Centogene (CNTG), Fulgent Genetics (FLGT), DermTech (DMTK), Enzo Biochem (ENZ), Celcuity (CELC), Anpac Bio-Medical Science (ANPC), Biocept (BIOC) and Miragen Therapeutics (MGEN). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), CA (CA), Crispr Therapeutics (CRSP), AbbVie (ABBV), Advanced Micro Devices (AMD), Endologix (ELGX), BlackRock (BLK), InVitae (NVTA), Gilead Sciences (GILD) and Alibaba Group (BABA).

Veracyte trades on the NASDAQ under the ticker symbol "VCYT."

Veracyte's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include William Blair Investment Management LLC (8.91%), BlackRock Inc. (8.43%), Sumitomo Mitsui Trust Holdings Inc. (6.61%), Nikko Asset Management Americas Inc. (6.57%), Nikko Asset Management Americas Inc. (6.57%) and Invesco Ltd. (6.44%). Company insiders that own Veracyte stock include Bonnie H Anderson, Christopher M Hall, Evan/ Fa Jones, Giulia C Kennedy, Jesse I Treu, John Walter Hanna Jr and Keith Kennedy. View institutional ownership trends for Veracyte.

VCYT stock was sold by a variety of institutional investors in the last quarter, including Driehaus Capital Management LLC, Lord Abbett & CO. LLC, Nuveen Asset Management LLC, Invesco Ltd., Two Sigma Advisers LP, Acadian Asset Management LLC, Squarepoint Ops LLC, and Atom Investors LP. Company insiders that have sold Veracyte company stock in the last year include Bonnie H Anderson, Evan/ Fa Jones, Giulia C Kennedy, John Walter Hanna Jr, and Keith Kennedy. View insider buying and selling activity for Veracyte.

VCYT stock was purchased by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, William Blair Investment Management LLC, Loomis Sayles & Co. L P, Nikko Asset Management Americas Inc., Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., GW&K Investment Management LLC, and New York State Common Retirement Fund. View insider buying and selling activity for Veracyte.

Shares of VCYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of VCYT stock can currently be purchased for approximately $25.59.

Veracyte has a market capitalization of $1.28 billion and generates $120.37 million in revenue each year. The biotechnology company earns $-12,600,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis. Veracyte employs 270 workers across the globe.

The official website for Veracyte is www.veracyte.com.

Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-243-6300 or via email at [email protected]